Regeneron Pharmaceuticals, Inc. (REGN) Stock Analysis

Regeneron Pharmaceuticals (REGN) is a science-led, fully integrated biopharmaceutical company commercializing Dupixent, Eylea/Eylea HD, Libtayo, and Lynozyfic across immunology, ophthalmology, oncology, and rare diseases. Its internal genetics, antibody-generation, development, and manufacturing platforms allow it to capture value across the drug lifecycle and reduce dependence on external licensing. **The central investment debate is whether Eylea HD can replace deteriorating Eylea 2 mg economics before Vabysmo and aflibercept biosimilars accelerate erosion.** Q2 2026 revenue increased 17% year over year to $4.291 billion, beating consensus by $471 million-$491 million, while non-GAAP EPS of $14.29 exceeded estimates by $3.71-$4.13. Dupixent collaboration revenue rose 51% to $2.174 billion, reflecting global Dupixent sales of $6.0 billion, up 38% at constant currency. The full repayment of the Sanofi Development Balance at Q2-end should increase profit sharing from Q3 2026, potentially adding $7-$10 to annualized EPS. At $695.42 and 16.9x trailing P/E, valuation appears conservative versus the approximately $809.50-$812.40 consensus target. Near-term catalysts include profit-share expansion, Eylea HD conversion, and second-half 2026 pipeline results.